866-997-4948(US-Canada Toll Free)

Esophageal Cancer - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Sep 2016

Category :

Cancer

No. of Pages : 429 Pages

Esophageal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Directs, Esophageal Cancer - Pipeline Review, H2 2016, provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Esophageal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Esophageal Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Esophageal Cancer - Overview 11
Pipeline Products for Esophageal Cancer - Comparative Analysis 12
Esophageal Cancer - Therapeutics under Development by Companies 13
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Esophageal Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Esophageal Cancer - Products under Development by Companies 21
Esophageal Cancer - Products under Investigation by Universities/Institutes 26
Esophageal Cancer - Companies Involved in Therapeutics Development 27
Adaptimmune Therapeutics Plc 27
Advaxis, Inc. 28
Advenchen Laboratories, LLC 29
Almac Discovery Limited 30
Amgen Inc. 31
ArQule, Inc. 32
Array BioPharma Inc. 33
Aslan Pharmaceuticals Pte. Ltd. 34
ATLAB Pharma SAS 35
Bayer AG 36
Betta Pharmaceuticals Co. Ltd. 37
Boehringer Ingelheim GmbH 38
Celgene Corporation 39
Celldex Therapeutics, Inc. 40
Cellectar Biosciences, Inc. 41
Cerulean Pharma, Inc. 42
Cyclacel Pharmaceuticals, Inc. 43
F. Hoffmann-La Roche Ltd. 44
Genmab A/S 45
GlaxoSmithKline Plc 46
Glycotope GmbH 47
Hutchison MediPharma Limited 48
Ignyta, Inc. 49
ImmunoFrontier, Inc. 50
Immunomedics, Inc. 51
Johnson & Johnson 52
Komipharm International Co., Ltd. 53
MacroGenics, Inc. 54
MaxiVAX SA 55
Mebiopharm Co., Ltd. 56
MedImmune, LLC 57
Merck & Co., Inc. 58
Mirna Therapeutics, Inc. 59
Novartis AG 60
Omeros Corporation 61
Omnitura Therapeutics Inc. 62
Oncolys BioPharma Inc 63
OncoMed Pharmaceuticals, Inc. 64
Ono Pharmaceutical Co., Ltd. 65
Pfizer Inc. 66
Proteo, Inc. 67
Puma Biotechnology, Inc. 68
Rhizen Pharmaceuticals S.A. 69
Shionogi & Co., Ltd. 70
Spectrum Pharmaceuticals, Inc. 71
Symphogen A/S 72
Taiho Pharmaceutical Co., Ltd. 73
Taiwan Liposome Company, Ltd. 74
Takara Bio Inc. 75
Transgene Biotek Limited 76
VioQuest Pharmaceuticals, Inc. 77
XuanZhu Pharma Co., Ltd. 78
Esophageal Cancer - Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Target 81
Assessment by Mechanism of Action 86
Assessment by Route of Administration 91
Assessment by Molecule Type 93
Drug Profiles 95
(tipiracil hydrochloride + trifluridine) - Drug Profile 95
1-BB1 - Drug Profile 101
ADXS-HER2 - Drug Profile 102
afatinib dimaleate - Drug Profile 106
AL-3818 - Drug Profile 117
ALM-301 - Drug Profile 119
alpelisib - Drug Profile 120
AMG-337 - Drug Profile 123
apatinib - Drug Profile 125
atezolizumab - Drug Profile 128
ATL-101 - Drug Profile 141
binimetinib - Drug Profile 143
brontictuzumab - Drug Profile 150
CDX-1401 - Drug Profile 153
Cellular Immunotherapy for Oncology - Drug Profile 156
Cellular Immunotherapy for Oncology - Drug Profile 157
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 158
Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile 159
cetuximab biobetter - Drug Profile 160
CGX-1321 - Drug Profile 162
CRLX-101 - Drug Profile 163
CYC-140 - Drug Profile 174
DKN-01 - Drug Profile 175
donafenib - Drug Profile 177
durvalumab - Drug Profile 178
elgemtumab - Drug Profile 188
erdafitinib - Drug Profile 190
futuximab - Drug Profile 192
ganetespib - Drug Profile 195
gedatolisib - Drug Profile 207
GSK-2256098 - Drug Profile 209
GSK-3377794 - Drug Profile 211
HMPL-309 - Drug Profile 217
I131-CLR1404 - Drug Profile 218
icotinib hydrochloride - Drug Profile 222
IMF-001 - Drug Profile 224
JS-001 - Drug Profile 225
KML-001 - Drug Profile 226
margetuximab - Drug Profile 228
MBP-426 - Drug Profile 231
miR-215 - Drug Profile 233
MMD-37K - Drug Profile 234
Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile 235
MVXONCO-1 - Drug Profile 236
neratinib - Drug Profile 237
nimotuzumab - Drug Profile 251
nintedanib - Drug Profile 255
nivolumab - Drug Profile 265
OBP-301 - Drug Profile 295
OMN-54 - Drug Profile 297
paclitaxel albumin bound - Drug Profile 299
panitumumab - Drug Profile 307
pasireotide ER - Drug Profile 312
PCA-062 - Drug Profile 315
pembrolizumab - Drug Profile 316
pralatrexate - Drug Profile 348
RXDX-106 - Drug Profile 353
S-222611 - Drug Profile 355
S-588410 - Drug Profile 356
sacituzumab - Drug Profile 358
SDS-eCAR - Drug Profile 366
sirotinib - Drug Profile 367
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 368
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 369
SMYD-2BAY02 - Drug Profile 370
TBI-1201 - Drug Profile 371
TBL-0805E - Drug Profile 373
TGR-1202 - Drug Profile 374
tiprelestat - Drug Profile 381
tisotumab vedotin - Drug Profile 385
tivantinib - Drug Profile 387
TLC-388 - Drug Profile 393
triciribine phosphate - Drug Profile 395
Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile 399
varlitinib - Drug Profile 400
YQ-23 - Drug Profile 403
Esophageal Cancer - Dormant Projects 404
Esophageal Cancer - Discontinued Products 409
Esophageal Cancer - Product Development Milestones 410
Featured News & Press Releases 410
Appendix 423
Methodology 423
Coverage 423
Secondary Research 423
Primary Research 423
Expert Panel Validation 423
Contact Us 423
Disclaimer 424

List of Tables
Number of Products under Development for Esophageal Cancer, H2 2016 16
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Number of Products under Development by Companies, H2 2016 (Contd..1) 19
Number of Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Development by Companies, H2 2016 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Late Stage Development, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Development, H2 2016 25
Products under Development by Companies, H2 2016 26
Products under Development by Companies, H2 2016 (Contd..1) 27
Products under Development by Companies, H2 2016 (Contd..2) 28
Products under Development by Companies, H2 2016 (Contd..3) 29
Products under Development by Companies, H2 2016 (Contd..4) 30
Products under Investigation by Universities/Institutes, H2 2016 31
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 32
Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2016 33
Esophageal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 34
Esophageal Cancer - Pipeline by Almac Discovery Limited, H2 2016 35
Esophageal Cancer - Pipeline by Amgen Inc., H2 2016 36
Esophageal Cancer - Pipeline by ArQule, Inc., H2 2016 37
Esophageal Cancer - Pipeline by Array BioPharma Inc., H2 2016 38
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016 39
Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 40
Esophageal Cancer - Pipeline by Bayer AG, H2 2016 41
Esophageal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 42
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 43
Esophageal Cancer - Pipeline by Celgene Corporation, H2 2016 44
Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 45
Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016 46
Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016 47
Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 48
Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 49
Esophageal Cancer - Pipeline by Genmab A/S, H2 2016 50
Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 51
Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2016 52
Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016 53
Esophageal Cancer - Pipeline by Ignyta, Inc., H2 2016 54
Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2016 55
Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2016 56
Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2016 57
Esophageal Cancer - Pipeline by Komipharm International Co., Ltd., H2 2016 58
Esophageal Cancer - Pipeline by MacroGenics, Inc., H2 2016 59
Esophageal Cancer - Pipeline by MaxiVAX SA, H2 2016 60
Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016 61
Esophageal Cancer - Pipeline by MedImmune, LLC, H2 2016 62
Esophageal Cancer - Pipeline by Merck & Co., Inc., H2 2016 63
Esophageal Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016 64
Esophageal Cancer - Pipeline by Novartis AG, H2 2016 65
Esophageal Cancer - Pipeline by Omeros Corporation, H2 2016 66
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016 67
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016 68
Esophageal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 69
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 70
Esophageal Cancer - Pipeline by Pfizer Inc., H2 2016 71
Esophageal Cancer - Pipeline by Proteo, Inc., H2 2016 72
Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016 73
Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 74
Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016 75
Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 76
Esophageal Cancer - Pipeline by Symphogen A/S, H2 2016 77
Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 78
Esophageal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 79
Esophageal Cancer - Pipeline by Takara Bio Inc., H2 2016 80
Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2016 81
Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016 82
Esophageal Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 83
Assessment by Monotherapy Products, H2 2016 84
Assessment by Combination Products, H2 2016 85
Number of Products by Stage and Target, H2 2016 87
Number of Products by Stage and Mechanism of Action, H2 2016 92
Number of Products by Stage and Route of Administration, H2 2016 97
Number of Products by Stage and Molecule Type, H2 2016 99
Esophageal Cancer - Dormant Projects, H2 2016 409
Esophageal Cancer - Dormant Projects (Contd..1), H2 2016 410
Esophageal Cancer - Dormant Projects (Contd..2), H2 2016 411
Esophageal Cancer - Dormant Projects (Contd..3), H2 2016 412
Esophageal Cancer - Dormant Projects (Contd..4), H2 2016 413
Esophageal Cancer - Discontinued Products, H2 2016 414

List of Figures
Number of Products under Development for Esophageal Cancer, H2 2016 16
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Products, H2 2016 25
Assessment by Monotherapy Products, H2 2016 84
Number of Products by Top 10 Targets, H2 2016 86
Number of Products by Stage and Top 10 Targets, H2 2016 86
Number of Products by Top 10 Mechanism of Actions, H2 2016 91
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 91
Number of Products by Top 10 Routes of Administration, H2 2016 96
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 96
Number of Products by Top 10 Molecule Types, H2 2016 98
Number of Products by Stage and Top 10 Molecule Types, H2 2016 98

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *